JP2022517216A - 組換え抗ヒトｐｄ－１抗体およびその用途 - Google Patents

組換え抗ヒトｐｄ－１抗体およびその用途 Download PDF

Info

Publication number
JP2022517216A
JP2022517216A JP2021540076A JP2021540076A JP2022517216A JP 2022517216 A JP2022517216 A JP 2022517216A JP 2021540076 A JP2021540076 A JP 2021540076A JP 2021540076 A JP2021540076 A JP 2021540076A JP 2022517216 A JP2022517216 A JP 2022517216A
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
fragment
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021540076A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022517216A5 (https=
JPWO2020143749A5 (https=
Inventor
ジンチャオ チャン
ロンジュアン ワン
シャシャ チャオ
シュアン ワン
Original Assignee
マブウェル （シャンハイ） バイオサイエンス カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マブウェル （シャンハイ） バイオサイエンス カンパニー リミテッド filed Critical マブウェル （シャンハイ） バイオサイエンス カンパニー リミテッド
Publication of JP2022517216A publication Critical patent/JP2022517216A/ja
Publication of JP2022517216A5 publication Critical patent/JP2022517216A5/ja
Publication of JPWO2020143749A5 publication Critical patent/JPWO2020143749A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2021540076A 2019-01-10 2020-01-10 組換え抗ヒトｐｄ－１抗体およびその用途 Pending JP2022517216A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910022548.9A CN111423510B (zh) 2019-01-10 2019-01-10 重组抗人pd-1抗体及其应用
CN201910022548.9 2019-01-10
PCT/CN2020/071353 WO2020143749A1 (zh) 2019-01-10 2020-01-10 重组抗人pd-1抗体及其应用

Publications (3)

Publication Number Publication Date
JP2022517216A true JP2022517216A (ja) 2022-03-07
JP2022517216A5 JP2022517216A5 (https=) 2023-01-20
JPWO2020143749A5 JPWO2020143749A5 (https=) 2023-01-20

Family

ID=71521975

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021540076A Pending JP2022517216A (ja) 2019-01-10 2020-01-10 組換え抗ヒトｐｄ－１抗体およびその用途

Country Status (8)

Country Link
US (1) US20230104769A1 (https=)
EP (1) EP3919514A4 (https=)
JP (1) JP2022517216A (https=)
KR (1) KR20210113635A (https=)
CN (1) CN111423510B (https=)
CA (1) CA3126302A1 (https=)
TW (1) TW202043271A (https=)
WO (1) WO2020143749A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022012428A1 (zh) * 2020-07-14 2022-01-20 迈威(上海)生物科技股份有限公司 抗pd-1抗体及其稳定制剂
EP4261225A4 (en) * 2020-12-10 2024-11-13 Eutilex Co., Ltd. ANTI-PD-1 ANTIBODY AND ITS USES
CN115925954A (zh) * 2022-12-28 2023-04-07 广州誉衡生物科技有限公司 抗-pd-1抗体及其在制备治疗尿路上皮癌患者的药物中的用途
WO2025102227A1 (zh) * 2023-11-14 2025-05-22 成都盛世君联生物技术有限公司 一种抗pd-1抗体及其生物材料和产品

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017096026A1 (en) * 2015-12-02 2017-06-08 Stcube, Inc. Antibodies specific to glycosylated pd-1 and methods of use thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
US8927697B2 (en) 2008-09-12 2015-01-06 Isis Innovation Limited PD-1 specific antibodies and uses thereof
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
MY184154A (en) 2013-12-12 2021-03-23 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
KR102524920B1 (ko) * 2014-07-22 2023-04-25 아폴로믹스 인코포레이티드 항-pd-1 항체
CN105330740B (zh) 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
WO2017019846A1 (en) * 2015-07-30 2017-02-02 Macrogenics, Inc. Pd-1-binding molecules and methods use thereof
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
US10981991B2 (en) * 2015-09-29 2021-04-20 Shanghai Zhangjiang Biotechnology Co., Ltd. PD-1 antibodies and uses thereof
CN106632674B (zh) * 2015-10-30 2018-11-16 泽达生物医药有限公司 一种抗pd-1单克隆抗体、其药物组合物及其用途
CN106699889A (zh) * 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
CN108079292A (zh) * 2016-11-23 2018-05-29 苏州盛迪亚生物医药有限公司 一种抗pd-1抗体在制备治疗肝癌的药物中的用途
CN107446048B (zh) * 2017-09-13 2021-03-30 北京韩美药品有限公司 一种能够特异性地结合pd-1的抗体及其功能片段
CN108218988B (zh) * 2017-11-29 2019-10-11 广西医科大学 抗PD-1的纳米抗体PD-1/Nb52及其制备方法与应用
CN108727504B (zh) * 2018-04-16 2021-08-27 泉州向日葵生物科技有限公司 一种ifn与抗pd-l1抗体的融合蛋白及其应用
CA3143034A1 (en) * 2019-06-14 2020-12-17 Cugene Inc. Novel interleukin-2 variants for the treatment of cancer
JP7807076B2 (ja) * 2019-12-13 2026-01-27 キュージーン インコーポレイテッド 新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用
MX2022007202A (es) * 2019-12-13 2022-10-07 Cugene Inc Fármacos bioactivables a base de citocinas y metodos de uso de los mismos.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017096026A1 (en) * 2015-12-02 2017-06-08 Stcube, Inc. Antibodies specific to glycosylated pd-1 and methods of use thereof

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ACTA PHARMACOLOGICA SINICA, vol. 38, JPN6023047790, 2017, pages 710 - 718, ISSN: 0005321295 *
CANCER, vol. 125, no. 5, JPN6023047792, 2018, pages 742 - 749, ISSN: 0005201196 *
IMMUNOLOGY TODAY, vol. 14, no. 6, JPN6023047796, 1993, pages 243 - 246, ISSN: 0005201200 *
J. MOL. BIOL., vol. 224, no. 2, JPN6023047797, 1992, pages 487 - 499, ISSN: 0005201201 *
JOURNAL OF IMMNOTHERAPY OF CANCER, vol. Vol.5, Suppl.2, JPN6023047789, 2017, pages 87 - 364, ISSN: 0005321294 *
PROC. NATL. ACD. SCI.USA, vol. 79, JPN6023047795, 1982, pages 1979 - 1983, ISSN: 0005201199 *
RESEARCH IN IMMUNOLOGY, vol. 145, no. 1, JPN6023047794, 1994, pages 33 - 36, ISSN: 0005201198 *
THE EMBO JOURNAL, vol. 14, no. 12, JPN6023047793, 1995, pages 2784 - 2794, ISSN: 0005201197 *
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 379, no. 4, JPN6023047791, 2018, pages 341 - 351, ISSN: 0005201195 *

Also Published As

Publication number Publication date
WO2020143749A1 (zh) 2020-07-16
CA3126302A1 (en) 2020-07-16
EP3919514A4 (en) 2022-12-07
US20230104769A1 (en) 2023-04-06
EP3919514A1 (en) 2021-12-08
TW202043271A (zh) 2020-12-01
CN111423510A (zh) 2020-07-17
KR20210113635A (ko) 2021-09-16
CN111423510B (zh) 2024-02-06

Similar Documents

Publication Publication Date Title
US12479919B2 (en) Anti-CTLA4 and anti-PD-1 bifunctional antibody, pharmaceutical composition thereof and use thereof
US11161904B2 (en) Anti-PD-1 antibody and use thereof
JP7393337B2 (ja) 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途
JP2020532965A (ja) 抗ｃｄ１３７分子及びその使用
CN114478769B (zh) 抗tigit抗体、其药物组合物及用途
JP2024528682A (ja) 薬物組成物及び用途
WO2023040945A1 (zh) 特异性结合pd-1的蛋白及其医药用途
JP2022517216A (ja) 組換え抗ヒトｐｄ－１抗体およびその用途
TW202337908A (zh) 抗b7-h7抗體或其抗原結合片段及製備方法與應用
WO2023040940A1 (zh) Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症
CN114341170A (zh) 一种人源化抗vegfr2抗体及其应用
CN107250162A (zh) 新的人源化adam17抗体
RU2779128C2 (ru) Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение
WO2025157266A1 (zh) 一种Nectin-4抗体及其应用
HK40089230A (zh) 药物组合物及用途
CN113929781A (zh) 抗pd-1抗体及其稳定制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230106

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240220

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240513